Micah Chiles
Group Product Director, HCP Professional Promotion, Lung Cancer
Johnson & Johnson
Three Indication and One Visionary
“With a calm demeanor and strategic mindset, Micah helps adroitly shepherd his team through many vital decisions for RYBREVANT®”
In one year, Micah Chiles was charged with prepping for multiple indication launches for a lung cancer product. RYBREVANT®, a treatment already approved for patients with lung cancer and a rare type of EGFR mutation, had data presented for three major phase III trials, setting 2024 to be an exciting year for the brand and for patients living with this devastating disease. Micah was the leader trusted to navigate the brand through the many complexities and challenges that came with this new movement.
With a calm demeanor and strategic mindset, Micah helps adroitly shepherd his team through many vital decisions for the brand. Micah’s team pieces out how to approach discussions surrounding the different indications of the therapy with the same HCPs without creating confusion or mixing brand identity. In addition, Micah’s team navigates the challenge of promoting an infusion-dosed brand in a space accustomed to oral treatments while preparing HCPs to proactively take care of their patients through potential early side effects so that they can later get the full benefits of longer protected life. Through all of these brand challenges, Micah’s steady leadership consistently manages to improve communication and alignment with multi-disciplinary stakeholders worldwide to promote the kind of efficiencies that allow the RYBREVANT team to stay in lock step with global counterparts.
“Micah is an innovative, analytical, and people-centric leader,” says Pavan Jagannathan, Senior Manager, Oncology Marketing at Johnson & Johnson. “His energy is infectious and inspires others to be the best versions of themselves, while creating meaningful and lasting impact for patients. Micah has been imperative for setting the direction of RYBREVANT in this key year for the brand. And on March 1, 2024 that direction bore its first fruit. RYBREVANT officially received its first new indication for patients with newly diagnosed NSCLC and the EGFR exon 20 insertion.
Micah sees no silos when it comes to cross-functional teams within J&J, and his ONE team mindset ensures that all parties feel aligned to the path forward for patients. His transparent and open-minded approach means that all stakeholders are better aligned with the vision of the brand’s future, and ultimately, lung cancer patients are better served.
